Actemra

INDICATIONS AND USAGE（适应症）

 

Rheumatoid Arthritis (RA)

ACTEMRA® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

 

Giant Cell Arteritis (GCA)

ACTEMRA® (tocilizumab) is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

 

Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

ACTEMRA® (tocilizumab) is indicated for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease.

 

Polyarticular Juvenile Idiopathic Arthritis (PJIA)

ACTEMRA® (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.

 

Systemic Juvenile Idiopathic Arthritis (SJIA)

ACTEMRA® (tocilizumab) is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

 

Cytokine Release Syndrome (CRS)

ACTEMRA® (tocilizumab) is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.

 

DOSAGE（服用剂量）

 

Rheumatoid Arthritis

ACTEMRA may be used as monotherapy or concomitantly with methotrexate or other non-biologic DMARDs as an intravenous infusion or as a subcutaneous injection.

Recommended Intravenous Dosage Regimen:

The recommended dosage of ACTEMRA for adult patients given as a 60-minute single intravenous drip infusion is 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response.

Reduction of dose from 8 mg per kg to 4 mg per kg is recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia.

Doses exceeding 800 mg per infusion are not recommended in RA patients.

Recommended Subcutaneous Dosage Regimen:

162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response for patients less than 100 kg weight,

162 mg administered subcutaneously every week for patients at or above 100 kg weight.

When transitioning from ACTEMRA intravenous therapy to subcutaneous administration administer the first subcutaneous dose instead of the next scheduled intravenous dose.

Interruption of dose or reduction in frequency of administration of subcutaneous dose from every week to every other week dosing is recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia.

 

Giant Cell Arteritis

The recommended dose of ACTEMRA for adult patients with GCA is 162 mg given once every week as a subcutaneous injection in combination with a tapering course of glucocorticoids.

A dose of 162 mg given once every other week as a subcutaneous injection in combination with a tapering course of glucocorticoids may be prescribed based on clinical considerations.

ACTEMRA can be used alone following discontinuation of glucocorticoids.

Interruption of dosing may be needed for management of dose-related laboratory abnormalities including elevated liver enzymes, neutropenia, and thrombocytopenia.

Intravenous administration is not approved for GCA.

 

Systemic Sclerosis-Associated Interstitial Lung Disease

The recommended dose of ACTEMRA for adult patients with SSc-ILD is 162 mg given once every week as a subcutaneous injection.

Interruption of dosing may be needed for management of dose-related laboratory abnormalities including elevated liver enzymes, neutropenia, and thrombocytopenia.

Subcutaneous administration with the prefilled ACTPen® autoinjector has not been studied in SSc-ILD.

Intravenous administration is not approved for SSc-ILD.

 

Polyarticular Juvenile Idiopathic Arthritis

ACTEMRA may be used as an intravenous infusion or as a subcutaneous injection alone or in combination with methotrexate. Do not change dose based solely on a single visit body weight measurement, as weight may fluctuate.

Recommended Intravenous Dosage Regimen:

 

The recommended dosage of ACTEMRA for PJIA patients given once every 4 weeks as a 60-minute single intravenous drip infusion is:

10 mg per kg for patients less than 30 kg weight,

8 mg per kg for patients at or above 30 kg weight.

Recommended Subcutaneous Dosage Regimen:

162 mg once every 3 weeks for patients less than 30 kg weight,

162 mg once every 2 weeks for patients at or above 30 kg weight.

 

Systemic Juvenile Idiopathic Arthritis

ACTEMRA may be used as an intravenous infusion or as a subcutaneous injection alone or in combination with methotrexate. Do not change a dose based solely on a single visit body weight measurement, as weight may fluctuate.

Recommended Intravenous Dosage Regimen:

The recommended dose of ACTEMRA for SJIA patients given once every 2 weeks as a 60-minute single intravenous drip infusion is:  

12 mg per kg for patients less than 30 kg weight,

8 mg per kg for patients at or above 30 kg weight.

Recommended Subcutaneous Dosage Regimen:

162 mg once every two weeks for patients less than 30 kg weight,

162 mg once every week for patients at or above 30 kg weight.

 

Cytokine Release Syndrome (CRS)

Use only the intravenous route for treatment of CRS. The recommended dose of ACTEMRA for treatment of CRS given as a 60-minute intravenous infusion is:

12 mg per kg for patients less than 30 kg weight,

8 mg per kg for patients at or above 30 kg weight.

If no clinical improvement in the signs and symptoms of CRS occurs after the first dose, up to 3 additional doses of ACTEMRA may be administered. The interval between consecutive doses should be at least 8 hours.

Doses exceeding 800 mg per infusion are not recommended in CRS patients.

 

ADVERSE REACTIONS（不良反应）

 

Serious Infections

Gastrointestinal Perforations

Laboratory Parameters

Immunosuppression

Hypersensitivity Reactions, Including Anaphylaxis

Demyelinating Disorders

Active Hepatic Disease and Hepatic Impairment

 

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13/spl-doc?hl=tocilizumab

Actemrainformation